P. Hartigan

发表

J. Hartigan, P. Hartigan, 1985 .

An evaluation of central laboratories in three VA cooperative studies.

P. Peduzzi, P. Hartigan, G. Johnson, 1990, Statistics in medicine.

Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424.

D. Berman, L. Shaw, J. Spertus, 2006, American heart journal.

A Comparison of Angioplasty With Medical Therapy in the Treatment of Single-Vessel Coronary Artery Disease

P. Hartigan, E. Folland, A. Parisi, 1992 .

Optimal medical therapy with or without PCI for stable coronary disease.

D. Berman, L. Shaw, J. Spertus, 2007, The New England journal of medicine.

Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial).

D. Berman, J. Spertus, P. Hartigan, 2015, The American journal of cardiology.

Predicting outcomes in HIV-infected veterans: II. Survival after AIDS.

P. Hartigan, L. Rabeneck, N. Wray, 1997, Journal of clinical epidemiology.

Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.

D. Berman, L. Shaw, J. Spertus, 2009, The American journal of cardiology.

The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.

D. Berman, L. Shaw, J. Spertus, 2007, The American journal of cardiology.

Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.

G. Dagenais, R. Frye, B. Chaitman, 2018, Atherosclerosis.

Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial.

D. Berman, J. Spertus, P. Hartigan, 2018, Journal of the American College of Cardiology.

Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).

J. Spertus, B. Chaitman, P. Hartigan, 2013, Journal of the American College of Cardiology.

Predicting outcomes in HIV-infected veterans: I. Progression to AIDS.

P. Hartigan, L. Rabeneck, N. Wray, 1997, Journal of clinical epidemiology.

Rationale and design of the National Emphysema Treatment Trial (NETT): A prospective randomized trial of lung volume reduction surgery.

Sarah E. Duffy, D. Sugarbaker, S. Piantadosi, 1999, The Journal of thoracic and cardiovascular surgery.

Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.

J. Spertus, A. Jacobs, B. Chaitman, 2016, American heart journal.

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.

P. Guarino, P. Hartigan, J. Gaziano, 2007, JAMA.

Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study

P. Lavori, P. Hartigan, J. Gaziano, 2004, Clinical trials.

Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes.

V. Fuster, R. Frye, B. Chaitman, 2019, Journal of the American College of Cardiology.

Seroprevalence and seroincidence of HIV-1 in injection drug users using the VA system.

P. Hartigan, J. Hamilton, 1994, AIDS research and human retroviruses.

Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single-vessel coronary artery disease. The Veterans Affairs ACME Investigators.

P. Hartigan, E. Bates, E. Folland, 1994, Circulation.

Single-Vessel Coronary Artery Disease

P. Hartigan, E. Bates, E. Folland, 2005 .

Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy: Observations From the COURAGE Trial

D. Berman, L. Shaw, J. Spertus, 2011, Circulation. Cardiovascular interventions.

Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial

D. Berman, L. Shaw, J. Spertus, 2009, Circulation. Cardiovascular quality and outcomes.

Predicting progression to AIDS

P. Hartigan, L. Rabeneck, J. Souchek, 1996, Journal of General Internal Medicine.

Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS.

P. Hartigan, E. Folland, A. Parisi, 1997, Journal of the American College of Cardiology.

Importance of cerebrovascular disease in studies of myocardial infarction.

J. Concato, P. Hartigan, L. Brass, 1996, Stroke.

A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators.

P. Hartigan, E. Folland, A. Parisi, 1992, The New England journal of medicine.

Angina-free time on the treadmill as an alternate method for evaluating antianginal therapy. Veterans Affairs ACME Investigators.

P. Hartigan, E. Folland, A. Parisi, 1994, The American journal of cardiology.

Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial

Daniel S Berman, Mihaela Aslan, Paul Kolm, 2013, Circulation. Cardiovascular quality and outcomes.

Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

J. Spertus, Binita Shah, B. Chaitman, 2022, The American journal of cardiology.

Relation Between Coronary Artery Stenosis Assessed by Visual, Caliper, and Computer Methods and Exercise Capacit in Patients With Single-Vessel Coronary Artery Disease

P. Hartigan, E. Bates, E. Folland, 2005 .

Costeffectiveness analysis ofearly zidovudine treatment of HIVinfected patients

P. Hartigan, P. Cowper, M. Simberkoff, 1993 .

Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post hoc analysis of the COURAGE trial).

D. Berman, L. Shaw, J. Spertus, 2012, The American journal of cardiology.

Cost effectiveness of treating asymptomatic HIV infection.

P. Hartigan, J. Hamilton, M. Simberkoff, 1991, Annals of internal medicine.

A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy. Outcomes of a randomized clinical trial. Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators.

P. Hartigan, E. Folland, A. Parisi, 1995, Circulation.

Immunoregulatory abnormalities in children with thrombocytopenic purpura.

P. Hartigan, J. Dwyer, S. Mcintosh, 1981, The Journal of pediatrics.

Immunoregulatory abnormalities thrombocytopenic purpura in children with

P. Hartigan, J. Dwyer, A. Baumgarten, 1981 .

The effect of zidovudine on patient subgroups.

P. Hartigan, J. Hamilton, M. Simberkoff, 1992, JAMA.

Treatment of mildly symptomatic human immunodeficiency virus (HIV) infection.

P. Hartigan, J. Hamilton, M. Simberkoff, 1990, Annals of internal medicine.

Optimal medical therapy with or without PCI for stable coronary disease.

D. Berman, L. Shaw, J. Spertus, 2007, The New England journal of medicine.

Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure

P. Hartigan, E. Daar, J. Hamilton, 1997, Annals of Internal Medicine.

Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy

Guido Germano, Daniel S Berman, Piotr Slomka, 2008, Circulation.

Acetylcholine inhibits positive inotropic effect of cholera toxin in ventricular muscle.

P. Hartigan, A. Pappano, M. Coutu, 1982, The American journal of physiology.

A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.

G L Drusano, S. Zolla-Pazner, P. Hartigan, 1992, The New England journal of medicine.

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

P. Hartigan, W. O'brien, J. Hamilton, 1996, The New England journal of medicine.

Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis. Veterans Affairs Cooperative Variceal Sclerotherapy Group.

P. Hartigan, R. Gebhard, P. Gregory, 1997, Gastrointestinal endoscopy.

Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease

D. Berman, L. Shaw, J. Spertus, 2019, Circulation. Cardiovascular quality and outcomes.

Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials.

P. Hartigan, W. Boden, David L. Brown, 2014, JAMA internal medicine.

Regina M. Hardison, P. Hartigan, W. Boden, 2014, JAMA internal medicine.

Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: Results of a randomized, multicenter clinical trial

P. Hartigan, 1994, Hepatology.

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes.

D. Berman, J. Spertus, P. Hartigan, 2019, Journal of the American College of Cardiology.

Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.

D. Berman, L. Shaw, J. Spertus, 2009, Journal of the American College of Cardiology.

Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study

P. Hartigan, W. O'brien, G. Drusano, 1996 .

Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)

D. Berman, J. Spertus, P. Hartigan, 2018, Circulation. Cardiovascular quality and outcomes.

Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.

P. Guarino, P. Hartigan, J. Gaziano, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Detection of Ototoxicity by High-Frequency Auditory Evaluation

P. Hartigan, S. Fausti, B. Rappaport, 1985 .

Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine.

P. Hartigan, E. Folland, A. Parisi, 1998, The American journal of cardiology.

Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease.

J. Hartigan, J. Spertus, B. Chaitman, 2020, The American journal of cardiology.

The Cost-Effectiveness of Percutaneous Coronary Intervention as a Function of Angina Severity in Patients With Stable Angina

D. Berman, L. Shaw, J. Spertus, 2011, Circulation. Cardiovascular quality and outcomes.

Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) Study.

P. Hartigan, E. Folland, A. Parisi, 1997, Journal of the American College of Cardiology.

Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial.

Stanley E. Kaufman, R. Goeree, J. Spertus, 2006, American heart journal.

Clinical and socioeconomic determinants of health care use among HIV-infected patients in the Department of Veterans Affairs.

P. Hartigan, L. Rabeneck, N. Wray, 2000, Inquiry : a journal of medical care organization, provision and financing.

Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials.

M. Gail, J. Bartlett, R. Redfield, 1993, Controlled clinical trials.

Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.

D. Berman, G. Germano, L. Shaw, 2012, American heart journal.

Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.

D. Berman, L. Shaw, J. Spertus, 2010, Journal of the American College of Cardiology.

Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424

D. Berman, L. Shaw, P. Slomka, 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial).

J. Spertus, B. Chaitman, P. Hartigan, 2015, American Journal of Cardiology.

Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia.

D. Berman, L. Shaw, J. Spertus, 2014, JACC. Cardiovascular interventions.

Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.

J. Spertus, P. Hartigan, R. O'rourke, 2009, The American journal of cardiology.

Effect of PCI on quality of life in patients with stable coronary disease.

Stanley E. Kaufman, R. Goeree, J. Spertus, 2008, The New England journal of medicine.

Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease.

Daniel Berman, William S Weintraub, John A Spertus, 2015, The New England journal of medicine.

Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients

Ron Goeree, Claudine Jurkovitz, Emir Veledar, 2008, Circulation. Cardiovascular quality and outcomes.

Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial.

D. Berman, J. Spertus, B. Chaitman, 2013, American heart journal.

Risk factor control for coronary artery disease secondary prevention in large randomized trials.

V. Fuster, M. Domanski, R. Frye, 2013, Journal of the American College of Cardiology.

Computation of the Dip Statistic to Test for Unimodality

P. M. Hartigan, P. Hartigan, 1985 .

Do Major Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial Differ by Healthcare System?

L. Shaw, J. Spertus, B. Chaitman, 2010, Circulation. Cardiovascular quality and outcomes.

Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease.

V. Fuster, R. Frye, B. Chaitman, 2016, Journal of the American College of Cardiology.

Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization.

V. Fuster, R. Frye, B. Chaitman, 2020, Journal of the American College of Cardiology.

Percutaneous Transluminal Coronary Angioplasty Versus Medical Therapy for Stable Angina Pectoris: Outcomes for Patients With Double-Vessel Versus Single-Vessel Coronary Artery Disease in a Veterans Affairs Cooperative Randomized Trial

P. Hartigan, E. Folland, A. Parisi, 1997 .

Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).

P. Hartigan, W. Boden, W. Weintraub, 2013, The American journal of cardiology.

Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.

D. Berman, L. Shaw, J. Spertus, 2011, Journal of the American College of Cardiology.

A Comparison of Quality of Life Scores in Patients With Angina Pectoris After Angioplasty Compared With After Medical Therapy Outcomes of a Randomized Clinical Trial

P. Hartigan, E. Folland, A. Parisi, 1995 .

Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).

D. Berman, L. Shaw, J. Spertus, 2009, The American journal of cardiology.

An Application of the Cure Model to a Cardiovascular Clinical Trial

Shuangge Ma, P. Hartigan, V. Sevilimedu, 2020, Statistics in Biosciences.

Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).

J. Spertus, P. Hartigan, D. Goldfarb, 2013, The American journal of cardiology.

IMPACT OF PRETREATMENT ISCHEMIA ON THERAPEUTIC RISK REDUCTION AND LONG-TERM PROGNOSIS IN PATIENTS WITH STABLE ANGINA: RESULTS FROM COURAGE TRIAL

D. Berman, L. Shaw, J. Min, 2010 .

Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group.

S. Zolla-Pazner, P. Hartigan, N. Klimas, 1994, The Journal of infectious diseases.

Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group.

S. Zolla-Pazner, P. Hartigan, N. Klimas, 1994, The Journal of infectious diseases.

Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.

P. Hartigan, W. O'brien, G. Drusano, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Cost effectiveness analysis of early zidovudine treatment of HIV infected patients.

P. Hartigan, G. Samsa, D. Matchar, 1993, BMJ.

Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.

P. Hartigan, J. Hamilton, M. Simberkoff, 1993, Journal of acquired immune deficiency syndromes.

Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy

G. Germano, L. Shaw, P. Slomka, 2009 .

The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status.

P. Hartigan, R. O'rourke, W. Boden, 2006, Heart & lung : the journal of critical care.

Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: Results of a randomized, multicenter clinical trial

P. Hartigan, 1994, Hepatology.

L. Shaw, J. Spertus, B. Chaitman, 2011, Journal of the American College of Cardiology.

Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.

J. Spertus, P. Hartigan, R. O'rourke, 2009, The American journal of cardiology.

Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial).

J. Spertus, P. Hartigan, W. Boden, 2015, The American journal of cardiology.

Using the national registry of HIV-infected veterans in research: lessons for the development of disease registries.

N P Wray, P. Hartigan, L. Rabeneck, 2001, Journal of Clinical Epidemiology.